Site Strengths
- Experienced research coordinators with a special interest in diabetes
- Experienced investigators with 100+ clinical trials started
- High-quality research performance (FDA audit in 2017 with no findings)
- First ever research-based patient portal
- Multiple community relationships providing referrals for research
- Ability to use a Central IRB
- Clinical trial management software ensuring efficient organization of all research activities
We are a multi-center site in Central Iowa performing research in diabetes, diabetes-related conditions, and hormonal disorders.
Type 2 Diabetes
Type 1 Diabetes
Pumps, CGMs, Glucose Meters
NASH
Retinopathy
Kidney Disease
Obesity
Men’s Health (Low-T & Erectile Dysfunction)
Cardiovascular Disease
Partners We’ve Worked With
























Recruitment History
Iowa Diabetes Research has a strong history of success in trial recruitment, having over-recruited for a majority of studies we have done to date.
Our Patient Qualifier platform allows us to efficiently and effectively recruit study participants using real-time health data and communication features.
Most of our research patients join another study with us after they finish their current study because of our caring, passionate, and patient-centered staff.
Company/Medication | Enrollment Goal | Screened | Randomized | % Enrollment |
---|---|---|---|---|
Medtronic/Pump use in T1D | 12 | 51 | 41 | 342% |
GlaxoSmithKline/CV outcomes | 10 | 31 | 28 | 280% |
Gan and Lee/ Biosimilar insulin glargine in T2D | 12 | 31 | 23 | 192% |
Lilly/T2DM ultra rapid acting formula insulin lispro | 8 | 24 | 13 | 163% |
Gan and Lee/ Biosimilar insulin glargine in T1D | 12 | 27 | 19 | 158% |
Novo Nordisk/GLP-1 use for treatment of obesity | 7 | 16 | 11 | 157% |
Lilly/T1DM ultra rapid acting formula insulin lispro | 13 | 31 | 19 | 146% |
Boehringer Ingelheim/SGLT-2 in T1D | 36 | 50 | 48 | 133% |
Dexcom/CGM use in T1D and T2D | 50 | 59 | 55 | 110% |